Explore leading companies in the Life Sciences & BioTech category. Discover market leaders, emerging players, and innovative companies shaping this industry.
Filter by Tags
Available Tags
Ai Powered
Analytics
B2b
Enterprise
Fortune500
Global
Hardware
Healthtech
Iot
Manufacturing
Platform
Public
Saas
Startup
Technology
All Life Sciences & BioTech Brands
| Brand ↑ | Tags | Revenue | Market Share | Description |
|---|---|---|---|---|
| 10x Genomics | B2bGlobalPublicEnterpriseHealthtechHardwareAnalyticsPlatform | $642M | - | Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience... |
| AbCellera | B2bGlobalPublicHealthtechAi PoweredPlatformAnalytics | $75M | - | Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase ... |
| Absci | Ai PoweredTechnologyStartupHealthtechPlatformPublicB2b | - | - | Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the groun... |
| Addition Therapeutics | HealthtechB2b | $100M | - | Emerged from stealth with $100M (Dec 2025) backed by Gates Foundation, SR One, Abingworth. PRINT LNP platform integrates RNA at specific genomic loci ... |
| Aerska Therapeutics | HealthtechB2b | $39M | - | Raised $39M (Feb 2026, doubled from $21M Series A). Brain-shuttle + RNAi delivery for genetic Alzheimer's and Parkinson's. Non-viral CNS delivery cros... |
| Aevice Health | HealthtechIotAi PoweredStartupB2b | $30M | - | Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing ... |
| Agomab Therapeutics | HealthtechB2b | $200M | - | Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontunisertib in fibrostenosing Crohn's. Phase 1 data fo... |
| Alto Neuroscience | HealthtechB2b | $120M | - | Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-101. Biomarker-stratified psychiatry matching patien... |
| Alveus Therapeutics | HealthtechTechnologyStartupB2bGlobal | $150M | - | Alveus Therapeutics raised $150M Series A in 2025 for inhaled mRNA therapeutics targeting pulmonary diseases including idiopathic pulmonary fibrosis a... |
| Be Biopharma | HealthtechB2b | $274M | - | $274M total raised including $92M Series C with Bristol Myers Squibb. Phase 1/2 active for BE-101 in Hemophilia B. CRISPR-engineered B cells as contin... |
| Beam Therapeutics | StartupTechnologyHealthtechPublicB2b | - | - | Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double h... |
| BioNTech | B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform | - | - | German mRNA pioneer behind COVID-19 vaccine with Pfizer; pivoting to mRNA cancer immunotherapies and oncology pipeline across 20+ clinical programs.... |
| BrightHeart | HardwareHealthtechB2b | $11M | - | Raised €11M Series A (Jan 2026). FDA-cleared in 2025. Detects 96%+ of congenital heart defects in prenatal ultrasound. Distributed via GE HealthCare V... |
| Cognito Therapeutics | HardwareHealthtechB2b | $105M | - | Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device... |
| Cornerstone Robotics | HardwareHealthtechB2b | $200M | - | Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign wealth funds. China NMPA-approved. UK colorectal/urolo... |
| Cradle Bio | Ai PoweredStartupB2bSaasTechnologyHealthtech | - | - | Cradle provides an AI platform for protein engineering that accelerates the design of improved enzymes, antibodies, and other biologics for industrial... |
| Cytotheryx | HealthtechB2b | $60M | - | Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bio-incubators for human hepatocyte production at sc... |
| Earendil Labs | HealthtechB2b | $787M | - | Raised $787M (Mar 2026) backed by Sanofi, Pfizer/Hillhouse, DST Global. $2.56B Sanofi collaboration. 40+ AI-generated programs.... |
| eGenesis | HealthtechB2b | - | - | FDA-cleared IND for CRISPR-edited pig kidney (ESKD Phase 1/2/3). First patient dialysis-free at 7+ months post-transplant. 69-gene-edited pig — most c... |
| Eikon Therapeutics | HealthtechB2b | $381M | - | Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates ... |
| EpiBiologics | HealthtechB2b | $107M | - | Raised $107M Series B (Jan 2026) co-led by J&J Ventures and Google Ventures. EpiTAC targets membrane and secreted proteins — expanding degradation bey... |
| Finch Therapeutics | StartupHealthtechTechnologyPublicB2b | - | - | Finch Therapeutics develops microbiome-based medicines targeting the gut-brain and gut-immune axis with programs in autism spectrum disorder and C. di... |
| ForSight Robotics | HardwareHealthtechB2b | $125M | - | Raised $125M Series B (Jun 2025). First human cataract trials launching 2026. Oryom robot designed to reach any point within the eye.... |
| Gameto | HealthtechTechnologyStartupB2bGlobal | $70M | - | Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimulation duration from 10 days to 2–3 days, making f... |
| Genentech | B2bGlobalEnterprisePublicHealthtechManufacturingFortune500 | - | - | Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avasti... |
| Hemab Therapeutics | HealthtechB2b | $157M | - | Raised $157M oversubscribed Series C (Oct 2025) led by Sofinnova and Qatar Investment Authority. Sutacimig entering registration study 2026 for Glanzm... |
| Illumina | B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500 | $4340M | 80% | World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and populatio... |
| ImmunoVec | HealthtechB2b | $40.7M | - | Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune cells in vivo without viral vectors. Non-viral deli... |
| Infant Bacterial Therapeutics | HealthtechTechnologyStartupB2bPublic | - | - | Infant Bacterial Therapeutics (IBT) is developing live biotherapeutic Lactobacillus reuteri DSM17938 for necrotizing enterocolitis prevention in prema... |
| Insitro | Ai PoweredStartupTechnologyAnalyticsHealthtechB2b | - | - | Insitro integrates machine learning with high-throughput biology to discover and develop drugs faster by building predictive models of disease.... |
| Life Biosciences | HealthtechB2b | $80M | - | Closed $80M Series D (Apr 2026). FDA-cleared IND for ER-100 in optic neuropathies (Jan 2026). Phase 1 enrolling. Co-founded by Harvard's David Sinclai... |
| Lyell Immunopharma | StartupTechnologyHealthtechPublicB2b | - | - | Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaustion and treat solid tumors, the frontier of cell t... |
| Mantis Biotech | HealthtechB2b | $48M | - | Raised $48M Series A led by a16z Bio and GV (Feb 2026). YC-backed. Digital twins of human physiology to generate diverse synthetic trial data.... |
| Microbiotica | HealthtechTechnologyStartupB2bGlobal | $105M | - | Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products... |
| Mirador Therapeutics | HealthtechB2b | $250M | - | Raised $250M Series B (Jan 2026). $650M+ total raised. Mirador360 genetics-first platform. 10+ clinical readouts by end of 2027. Pipeline spans Crohn'... |
| Muna Therapeutics | HealthtechTechnologyStartupB2bGlobal | $75M | - | Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPSC-derived microglia models to identify novel drug ... |
| Nautilus Biotechnology | StartupTechnologyHealthtechAnalyticsPlatformPublicB2b | - | - | Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the full human proteome at a scale and sensitivity previo... |
| NEOK Bio | HealthtechTechnologyStartupB2bGlobal | $80M | - | NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of ... |
| NewLimit | HealthtechB2b | $130M | - | Raised $130M Series B (Kleiner Perkins) + $45M from Eli Lilly at $1.62B valuation. First demonstrated restoration of youthful killing function in aged... |
| NRG Therapeutics | HealthtechB2b | $50M | - | Raised £50M ($67M) oversubscribed Series B (Sep 2025). First participants dosed in Phase 1 of NRG5051 (Jan 2026). Phase 1 readout expected end of 2026... |
| Oxford Nanopore Technologies | B2bGlobalPublicHealthtechHardwareAnalyticsPlatform | $223M | - | UK nanopore sequencing pioneer with portable MinION device; £223M FY2025 revenue (+24% constant currency). Clinical revenues up 60% as sequencing move... |
| Pacific Biosciences | B2bGlobalPublicHealthtechHardwareAnalyticsPlatform | $170M | - | Pioneer of single-molecule real-time (SMRT) long-read sequencing; Revio system targets clinical and research markets. Guides to $150–$170M FY2025 reve... |
| PhaseV | HealthtechB2b | $50M | - | Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollment 40%, duration 40%. 40+ pharma sponsors. 7 of wo... |
| Pliant Therapeutics | HealthtechTechnologyPublicB2bStartup | - | - | Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in ... |
| Poplar Therapeutics | HealthtechB2b | $95M | - | Raised $95M total ($50M Series A Jan 2026 + $45M extension Mar 2026) from SR One, Vida, RA Capital, Janus Henderson. Triple-action anti-IgE mechanism.... |
| Prime Medicine | HealthtechB2b | $191M | - | Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing ... |
| Profluent Bio | Ai PoweredB2bHealthtechStartupTechnology | - | - | Profluent uses AI to design novel proteins and gene editors, including the first AI-created CRISPR system designed entirely from scratch.... |
| Regeneron | B2bGlobalPublicEnterpriseHealthtechManufacturingFortune500 | $14000M | - | Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific dr... |
| Relay Therapeutics | B2bStartupHealthtechAi PoweredPlatform | - | - | Cambridge MA precision oncology biotech using Dynamo platform to exploit protein motion for drug design; lead asset RLY-2608 targets PI3Kα in breast c... |
| Retro Biosciences | HealthtechB2b | $1000M | - | Raising $1B Series A at $5B valuation. Sam Altman-backed. Largest-funded pure-play longevity startup. First human trial targeting Australia launch.... |
| Rubedo Life Sciences | HealthtechB2b | $40M | - | $40M Series A. First patient dosed in Phase 1 for RLS-1496 — first GPX4 modulator targeting pathological senescent cells via ferroptosis. Novel senoly... |
| Sana Biotechnology | StartupHealthtechTechnologyPublicB2b | - | - | Sana Biotechnology develops engineered cell and gene therapies with fusogen delivery technology to treat serious diseases through in vivo and ex vivo ... |
| Schrödinger | B2bGlobalPublicEnterpriseHealthtechAi PoweredSaasPlatformAnalytics | $150M | - | Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in ... |
| Scribe Therapeutics | HealthtechB2b | $100M | - | Raised $100M Series B. Jennifer Doudna co-founder. Sanofi + Eli Lilly partnerships. STX-1150 (PCSK9 silencing via CasX-ELXR) IND projected mid-2026 — ... |
| Seres Therapeutics | StartupHealthtechTechnologyPublicB2b | - | - | Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral microbiome medicine for preventing recurrent C. diff... |
| Sidewinder Therapeutics | HealthtechTechnologyStartupB2bGlobal | $100M | - | Sidewinder Therapeutics raised $100M Series A in 2025 for its conditional activation platform that creates tumor-selective cancer drugs that only beco... |
| Solve Therapeutics | HealthtechB2b | $120M | - | Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLink ADC technology reduces hydrophobicity and toxic... |
| SpliceBio | HealthtechB2b | $135M | - | Raised $135M Series B led by Sanofi Ventures and EQT (Jun 2025). First patient dosed in Phase 1/2 for Stargardt disease (Jan 2026). Overcomes 4.7kb AA... |
| Stipple Bio | HealthtechB2b | $100M | - | Raised $100M oversubscribed Series A (Apr 2026) co-led by RA Capital and a16z Bio. Novel ADC platform targeting tumor-specific epitopes.... |
| Strand Therapeutics | HealthtechB2b | $153M | - | Raised $153M Series B (Aug 2025). $256M total. Programmable mRNA with SignalLock tumor-sensing logic gates. STX-003 IV delivery entering clinic 2026. ... |
| Third Arc Bio | HealthtechB2b | $52M | - | Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecific T cell engager, CLDN6+) in Phase 1 solid tumors.... |
| Timberlyne Therapeutics | HealthtechB2b | $180M | - | Raised $180M Series A (Jan 2025). CM313 achieved 95% response rate in treatment-refractory ITP in NEJM-published data. Multi-indication 2026 pipeline.... |
| Trace Neuroscience | HealthtechB2b | $101M | - | Launched with $101M Series A (Third Rock, Atlas, GV, RA Capital). TRCN-1023 (ASO for UNC13A mRNA splicing) entered ALS clinical testing in early 2026 ... |
| Tune Therapeutics | HealthtechB2b | $175M | - | Raised $175M Series B (Jan 2025) led by Hevolution, NEA, and Regeneron Ventures. First patient dosed in Phase 1/2 for chronic hepatitis B (Tune-401).... |
| Turn Biotechnologies | HealthtechB2b | $29M | - | Raised $29M Series A. Acquired ARMMs vesicular delivery tech (Mar 2025). Delivers mRNA cocktails that transiently reprogram aged cells to youthful epi... |
| Twist Bioscience | B2bGlobalPublicHealthtechManufacturingPlatformAnalytics | $376M | - | Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies synthetic genes to 3,000+ customers across biotech, p... |
| Umoja Biopharma | HealthtechTechnologyStartupB2bGlobal | $300M | - | Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting T-cells in a single IV infusion, eliminating the ... |
| Unity Biotechnology | HealthtechB2b | - | - | Positive 48-week Phase 2 BEHOLD data for UBX1325 in DME published in NEJM Evidence. Single-injection senolytic durability confirmed in diabetic macula... |
| Verdiva Bio | HealthtechTechnologyStartupB2bGlobal | $200M | - | Verdiva Bio raised $200M in 2025 for next-generation oral GLP-1 receptor agonists designed to match injectable semaglutide efficacy with once-daily or... |
| Verve Therapeutics | StartupTechnologyHealthtechPublicB2b | - | - | Verve Therapeutics develops single-course gene editing medicines for cardiovascular disease, aiming to permanently lower LDL cholesterol with one trea... |
| Vima Therapeutics | HealthtechB2b | $100M | - | Raised $100M Series A extended ($60M + $40M add-on after clinical data) from Atlas, Frazier, Access Industries. Only oral drug in development for isol... |
| Vivtex | HealthtechB2b | $2100M | - | Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer ... |
Total Brands
72
Signal Strength
15% Strong
11610
Last Updated
April 2026